These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Minutes of meeting, 30-31 May 1991. U.S. National Institutes of Health. Recombinant DNA Advisory Committee Hum Gene Ther; 1992 Feb; 3(1):95-121. PubMed ID: 11642989 [No Abstract] [Full Text] [Related]
4. Public oversight is necessary if human gene therapy is to progress. Zallen DT Hum Gene Ther; 1996 May; 7(7):795-7. PubMed ID: 8860831 [No Abstract] [Full Text] [Related]
5. National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986. Recomb DNA Tech Bull; 1986 Dec; 9(4):221-42. PubMed ID: 3469693 [No Abstract] [Full Text] [Related]
6. The revised "Points to Consider" document. Hum Gene Ther; 1990; 1(1):93-103. PubMed ID: 2081190 [No Abstract] [Full Text] [Related]
7. Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989. Recomb DNA Tech Bull; 1989 Sep; 12(3):151-70. PubMed ID: 2595016 [No Abstract] [Full Text] [Related]
8. Special informed consent requirements are included in protocol review procedures. Maloney DM Hum Res Rep; 1995 Jul; 10(7):1-2. PubMed ID: 11654274 [No Abstract] [Full Text] [Related]
9. Improved protection for human research subjects. Marwick C JAMA; 1998 Feb; 279(5):344-5. PubMed ID: 9459454 [No Abstract] [Full Text] [Related]
10. Gene therapy in the United States: a five-year status report. Ross G; Erickson R; Knorr D; Motulsky AG; Parkman R; Samulski J; Straus SE; Smith BR Hum Gene Ther; 1996 Sep; 7(14):1781-90. PubMed ID: 8886849 [No Abstract] [Full Text] [Related]
11. Recombinant DNA research; actions under guidelines; notice -- E. Points to consider for protocols for the transfer of recombinant DNA into the genome of human subjects. U.S. National Institutes of Health Fed Regist; 1990 Mar; 55(41):7443-7. PubMed ID: 11645685 [No Abstract] [Full Text] [Related]
12. Commentary: reconstruing genetic research as research. Lysaught MT J Law Med Ethics; 1998; 26(1):48-54, 4. PubMed ID: 11067585 [TBL] [Abstract][Full Text] [Related]
13. Human Gene Therapy Subcommittee: minutes of meeting, 30 Jul 1990. U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommittee Hum Gene Ther; 1991; 2(2):161-76. PubMed ID: 11642902 [No Abstract] [Full Text] [Related]
14. NIH guidelines for research involving recombinant DNA molecules. Wilson DJ Account Res; 1993; 3(2-3):177-85. PubMed ID: 11652293 [No Abstract] [Full Text] [Related]
16. Big changes at the RAC! Anderson WF Hum Gene Ther; 1994 Nov; 5(11):1309-10. PubMed ID: 7893801 [No Abstract] [Full Text] [Related]
17. Gene-splice oversight. Parens E Washington Post; 1996 Jun; ():A21. PubMed ID: 11646331 [No Abstract] [Full Text] [Related]
18. The NIH "Points to Consider" and the limits of human gene therapy. Juengst ET Hum Gene Ther; 1990; 1(4):425-33. PubMed ID: 2078585 [TBL] [Abstract][Full Text] [Related]
20. Minutes of meeting of the Human Gene Therapy Subcommittee, 30 Mar 1990. U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommitttee Hum Gene Ther; 1990; 1(4):481-91. PubMed ID: 11642815 [No Abstract] [Full Text] [Related] [Next] [New Search]